Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Reference Adalimumab in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy Genovese, M., Weinblatt, M., Keystone, E., Baranauskaite, A., Cheong, S., Ghil, J. J RHEUMATOL PUBL CO. 2017: 878
View details for Web of Science ID 000404641800086